Medtide Inc. Subsidiary Chinese Peptide Company Announces Successful Completion of U.S. FDA Pre-License Inspection (PLI) for Hepcludex® API, Establishing a Proven Track Record Under the Stringent BLA Pathway

MEDTIDE Executive Closed-Door Forum 2026 Concludes Successfully: Top-Level Dialogue Reshapes the Peptide Industry Landscape

Honored Milestone: Medtide Inc. Named in the "Top 20 Pharmaceutical CDMO Enterprises 2026"